Every treatment plan is personalised. Dr Ashwin K.R. reviews your scans, pathology and, where relevant, biomarker results with a multidisciplinary team, then recommends a sequence of treatment that fits your cancer and your health.
Looking for more detail? Read our complete guide with 55 patient FAQs: Gynecological Cancer Treatment FAQs.
Common questions, answered
Gynecological cancer questions answered →Many gynecological cancers can be cured, particularly when they are diagnosed at an early stage and treated by a specialist gynecologic oncology team.
Your chance of cure depends on:
What the evidence shows (five-year survival, approximate):
Gynecological cancer is any cancer that starts in a woman's reproductive organs: the ovaries, fallopian tubes, uterus, cervix, vagina or vulva.
The algorithm below shows how gynecological cancers are classified. Read it from left to right:
Figure 1. Algorithm of the types of gynecological cancer, their subtypes, key warning signs and main treatments
Why the exact type matters:
There are five main types of gynecological cancer: uterine (endometrial), ovarian (including fallopian tube and primary peritoneal), cervical, vulvar and vaginal cancer.
Table 1. Types of gynecological cancer at a glance
| Type of Cancer | Where It Starts | Key Facts |
|---|---|---|
| Uterine / Endometrial cancer | Lining of the womb (endometrium); rarely the uterine muscle (sarcoma) | Among the most common gynecological cancers; often found early because of abnormal bleeding |
| Ovarian cancer | Ovaries, fallopian tubes or peritoneum | Frequently diagnosed at an advanced stage; many high-grade serous cancers are thought to begin in the fallopian tube |
| Cervical cancer | Cervix (neck of the womb) | Nearly all cases are linked to persistent high-risk HPV infection; largely preventable with vaccination and screening |
| Vulvar cancer | Outer genital skin (vulva) | More common in older women; linked to HPV or chronic skin conditions such as lichen sclerosus |
| Vaginal cancer | Lining of the vagina | Rare; often HPV-related and usually treated with radiation |
| Gestational trophoblastic disease | Placental tissue after pregnancy | Rare; cure rates are very high, even when it has spread |
In most cases, nothing you did caused your cancer. Gynecological cancers usually result from a combination of genetic changes, hormones, infections such as HPV and ageing, most of which are outside anyone's control.
Table 2. Main risk factors by cancer type
| Cancer Type | Main Risk Factors |
|---|---|
| Uterine / Endometrial | Obesity, excess estrogen, diabetes, polycystic ovary syndrome (PCOS), never having been pregnant, late menopause, tamoxifen use, Lynch syndrome |
| Ovarian | Increasing age, BRCA1/BRCA2 mutations, Lynch syndrome, family history, endometriosis, never having been pregnant |
| Cervical | Persistent high-risk HPV infection, smoking, weakened immunity (e.g. HIV), lack of regular screening |
| Vulvar and Vaginal | HPV infection, smoking, lichen sclerosus, older age, weakened immunity |
Most women begin treatment within about two to six weeks of diagnosis, a timeframe generally considered appropriate for completing staging, planning and a second opinion if wanted.
Situations that may need urgent treatment:
Table 3. Typical timeline from diagnosis to treatment
| Step | What Happens | Typical Timeframe* |
|---|---|---|
| 1. First specialist consultation | History, examination, review of existing reports | Within 1 week of referral |
| 2. Staging tests | Blood tests, MRI / CT / PET-CT, additional biopsy if needed | 1–2 weeks |
| 3. Pathology review | Confirmation of type, grade and initial biomarkers | 3–7 working days |
| 4. Tumor board discussion | Multidisciplinary team agrees on the treatment plan | Within about 1 week of results |
| 5. Treatment plan consultation | Plan, alternatives, side effects and costs explained | Shortly after tumor board |
| 6. Treatment begins | Surgery, chemotherapy or radiation | About 2–6 weeks from diagnosis |
*Timeframes vary with your cancer, test availability and personal circumstances.
A second opinion is a normal, widely accepted part of cancer care, and most oncologists welcome it.
A second opinion is especially useful when:
Bring these to your second-opinion appointment:
Five-year survival rates for gynecological cancer range from over 90% for many early-stage cancers to below 30% for cancers that have spread to distant organs, which is why stage at diagnosis matters so much.
Table 4. Approximate five-year relative survival by stage
| Cancer Type | Localized (confined to organ) | Regional (nearby spread) | Distant (spread far) | All Stages |
|---|---|---|---|---|
| Uterine / Endometrial | ~95% | ~70% | ~18–19% | ~81% |
| Cervical | ~91% | ~60% | ~19% | ~67% |
| Ovarian | ~92% | ~73% | ~31% | ~51% |
| Vulvar | ~86% | ~51% | ~20% | ~70% |
| Vaginal | ~69% | ~57% | ~26% | ~51% |
Source: rounded approximations of U.S. SEER five-year relative survival, for general education only. Your oncologist can explain your individual outlook.
Your cancer stage describes how far the cancer has spread, and it is one of the most important factors in choosing treatment and estimating prognosis.
Table 5. FIGO stages explained
| Stage | General Meaning | Typical Treatment Approach |
|---|---|---|
| Stage I | Cancer is confined to the organ where it started | Surgery alone or with limited additional treatment; cure rates are high |
| Stage II | Spread to nearby pelvic structures (e.g. cervix, pelvic tissues, upper vagina) | Surgery and/or radiation, often with chemotherapy |
| Stage III | Spread to lymph nodes, the abdominal lining or further within the pelvis | Combination of surgery, chemotherapy and/or radiation, plus maintenance therapy where appropriate |
| Stage IV | Spread to the bladder, bowel lining or distant organs such as the liver or lungs | Systemic therapy (chemotherapy, targeted therapy, immunotherapy), with surgery or radiation in selected cases |
Advanced gynecological cancer is treatable: many women with stage 3 or stage 4 disease achieve remission, and some live for many years with good quality of life.
Tumor grade describes how abnormal the cancer cells look under the microscope and indicates how quickly the cancer is likely to grow and spread.
Table 6. Tumor grade explained
| Grade | What It Means |
|---|---|
| Low grade (Grade 1) | Cells look close to normal and usually grow slowly |
| Intermediate (Grade 2) | Cells are moderately abnormal |
| High grade (Grade 3) | Cells look very abnormal and tend to grow faster; usually treated more intensively |
Prognosis is shaped by the stage, type, grade and molecular profile of your cancer, how completely it can be treated, and your overall health.
Common warning signs of gynecological cancer include abnormal vaginal bleeding, persistent bloating, pelvic or abdominal pain and changes in the vulvar skin; symptoms lasting more than two weeks should be checked by a doctor.
Table 7. Common symptoms by cancer type
| Cancer Type | Common Symptoms |
|---|---|
| Uterine / Endometrial | Bleeding after menopause, bleeding between periods, heavier or prolonged periods, watery or blood-stained discharge, pelvic pain |
| Ovarian | Persistent bloating, abdominal swelling, feeling full quickly, loss of appetite, pelvic or abdominal pain, frequent or urgent urination, bowel changes, fatigue, unexplained weight loss |
| Cervical | Bleeding after sex, bleeding between periods or after menopause, unusual discharge, pelvic pain (early cervical cancer often has no symptoms) |
| Vulvar | Persistent itching, burning or pain, a lump, ulcer or wart-like growth, thickened or discolored skin |
| Vaginal | Abnormal bleeding or discharge, a lump in the vagina, pain during sex, painful urination |
These symptoms are more often caused by non-cancerous conditions, but they should still be assessed.
No, but bleeding after menopause is not considered normal and should be evaluated promptly, because it is the most common symptom of endometrial cancer.
Ovarian cancer is often called a “silent killer” because its early symptoms are vague and easily mistaken for digestive problems, so many cases are diagnosed after the cancer has spread.
Ovarian cancer is rarely completely silent. Watch for symptoms that are new, persistent and frequent (most days, for more than 2–3 weeks):
Next step: If these symptoms persist, ask your doctor about a pelvic examination, a transvaginal ultrasound and a CA-125 blood test.
See a doctor promptly for unexplained bleeding after menopause, bleeding after sex or symptoms lasting more than two weeks, and seek emergency care for heavy bleeding or severe pain.
Table 8. How urgently to seek care
| Symptom | Action |
|---|---|
| Heavy vaginal bleeding soaking a pad every hour for 2 hours or more | Go to emergency care |
| Severe or sudden abdominal or pelvic pain | Go to emergency care |
| Rapidly increasing abdominal swelling or difficulty breathing | Go to emergency care |
| Unable to pass urine or stool, or persistent vomiting | Seek same-day medical care |
| Bleeding after menopause or after sex | Book a doctor's appointment within days |
| New vulvar lump or sore that does not heal within 2 weeks | Book a doctor's appointment |
| Bloating or pelvic discomfort on most days for more than 2–3 weeks | Book a doctor's appointment |
Gynecological cancer is confirmed by examining tissue under the microscope, and a combination of examination, imaging and blood tests is used to determine the stage.
Table 9. Diagnostic and staging tests
| Test | Purpose |
|---|---|
| Pelvic and physical examination | Assesses the size and spread of any visible or palpable tumor |
| Transvaginal ultrasound | Measures endometrial thickness and examines the ovaries and uterus |
| Pap smear, HPV test and colposcopy | Detects abnormal cervical cells and guides cervical biopsy |
| Endometrial biopsy, hysteroscopy or D&C | Takes a tissue sample from the lining of the uterus |
| Tumor markers (CA-125, HE4, CEA, CA 19-9) | Supports diagnosis and tracks response to treatment |
| MRI of the pelvis | Shows local spread in cervical, endometrial and vulvar cancer |
| CT scan of chest, abdomen and pelvis | Checks for spread to lymph nodes, abdomen, liver and lungs |
| PET-CT scan | Detects spread to lymph nodes and distant sites |
| Image-guided or laparoscopic biopsy | Obtains tissue when the tumor is hard to reach |
| Molecular and genetic testing | Identifies features that guide targeted therapy and immunotherapy |
A biopsy, or tissue from surgery, is the standard way to confirm cancer, and most gynecological biopsies cause only mild, short-lived discomfort, although experiences vary.
CA-125 is a blood tumor marker that is raised in most women with advanced ovarian cancer, but a single CA-125 result cannot diagnose or rule out cancer on its own.
MRI and PET-CT scans show where the cancer is and whether it has spread, which is essential for accurate staging and treatment planning.
Table 10. Imaging scans compared
| Scan | What It Shows Best | Commonly Used For | Typical Duration |
|---|---|---|---|
| MRI pelvis | Detailed soft-tissue anatomy of the pelvis | Local spread of cervical, endometrial and vulvar cancer | 30–45 minutes |
| CT chest, abdomen and pelvis | Lymph nodes, abdominal spread, liver and lungs | Staging ovarian and endometrial cancer | 10–15 minutes |
| PET-CT | Metabolically active cancer throughout the body | Cervical cancer nodes, radiation planning, suspected recurrence | About 2 hours including preparation |
Biomarker testing analyses the genetic and molecular features of your tumor to identify which targeted therapies and immunotherapies are more likely to help you.
Table 11. Key biomarkers in gynecological cancer
| Biomarker | Cancer Type | Why It Matters |
|---|---|---|
| BRCA1 / BRCA2 mutation | Ovarian | Predicts benefit from PARP inhibitors; also relevant to family members |
| HRD (homologous recombination deficiency) | Ovarian | Identifies BRCA-negative tumors that may also benefit from PARP inhibitors |
| Mismatch repair (MMR) / MSI status | Endometrial, ovarian | dMMR/MSI-high tumors often respond to immunotherapy; may indicate Lynch syndrome |
| POLE mutation and p53 status | Endometrial | POLE-mutated tumors have a very favourable prognosis; p53-abnormal tumors usually need more intensive treatment |
| PD-L1 | Cervical | Helps select patients for immunotherapy |
| HER2 | Endometrial (serous), others | Allows HER2-targeted therapy |
| Folate receptor alpha (FRα) | Ovarian | Identifies eligibility for antibody-drug conjugate therapy |
Most biopsy results are available within about 3 to 7 working days, while specialised molecular and genetic tests usually take 2 to 4 weeks.
Table 12. Typical test result turnaround times
| Test | Typical Turnaround* | Can Treatment Start Before Results? |
|---|---|---|
| Blood tests and tumor markers | Same day to 2 days | Not applicable |
| CT / MRI report | Same day to 2 days | Not applicable |
| PET-CT report | 1–2 days | Not applicable |
| Biopsy (histopathology) | 3–7 working days | No – diagnosis must be confirmed first |
| Immunohistochemistry (IHC), MMR, p53 | Adds 2–5 working days | Sometimes |
| Tumor genomic tests (BRCA, HRD, POLE) | 2–4 weeks | Often yes – plan adjusted when results arrive |
| Germline (inherited) genetic testing | 2–4 weeks | Often yes |
*Turnaround times vary between laboratories.
The most suitable treatment depends on the type, stage, grade and molecular profile of your cancer, and it is decided by a multidisciplinary tumor board to fit your individual needs.
Table 13. Main treatments by cancer type and stage
| Cancer Type | Early Stage | Advanced Stage |
|---|---|---|
| Uterine / Endometrial | Hysterectomy with removal of tubes and ovaries, plus sentinel lymph node mapping; radiation or brachytherapy if risk features are present | Surgery, chemotherapy plus immunotherapy, radiation, hormone therapy and targeted therapy |
| Ovarian | Comprehensive staging surgery; chemotherapy for most stages beyond low-grade IA/IB | Cytoreductive (debulking) surgery and carboplatin–paclitaxel chemotherapy, followed by maintenance PARP inhibitor and/or bevacizumab |
| Cervical | Cone biopsy, trachelectomy or radical hysterectomy with lymph node assessment | Concurrent chemoradiation with brachytherapy, with immunotherapy in selected cases |
| Vulvar | Wide local excision with sentinel lymph node biopsy | Chemoradiation, with surgery in selected cases |
| Vaginal | Surgery or radiation | Chemoradiation with brachytherapy |
Most women with gynecological cancer have surgery, which is often central to both staging and treating the disease.
Table 14. Types of gynecological cancer surgery
| Procedure | What Is Removed or Done | Commonly Used For |
|---|---|---|
| Total hysterectomy with bilateral salpingo-oophorectomy | Uterus, cervix, fallopian tubes and ovaries | Endometrial and ovarian cancer |
| Radical hysterectomy | Uterus, cervix, upper vagina and surrounding tissues (parametrium) | Early cervical cancer |
| Radical trachelectomy | Cervix and surrounding tissue, preserving the uterus | Small early cervical cancer in women wishing to have children |
| Sentinel lymph node biopsy | Only the first draining lymph nodes, identified with a tracer dye | Endometrial, cervical and vulvar cancer |
| Cytoreductive (debulking) surgery | All visible tumor, sometimes including bowel, omentum or spleen | Advanced ovarian cancer |
| Wide local excision / radical vulvectomy | Tumor with a margin of healthy tissue | Vulvar cancer |
Table 15. Typical hospital stay and recovery after surgery
| Surgery | Hospital Stay* | Light Activity | Return to Desk Work* | Driving* |
|---|---|---|---|---|
| Robotic / laparoscopic hysterectomy | 1 night (0–2) | Within days | 2–4 weeks | About 2 weeks |
| Open (abdominal) hysterectomy | 3–5 days | 1–2 weeks | 6–8 weeks | 4–6 weeks |
| Radical hysterectomy / trachelectomy | 2–5 days | 1–2 weeks | 4–8 weeks | 3–6 weeks |
| Cytoreductive (debulking) surgery | 5–10 days | 2–3 weeks | 6–12 weeks | 4–6 weeks |
| Vulvar surgery | 1–5 days | 1–2 weeks | 3–8 weeks | 2–6 weeks |
*Recovery varies with the extent of surgery, your fitness and any complications. Drive only when you can perform an emergency stop comfortably and are not taking sedating pain medication.
Robotic and laparoscopic (keyhole) surgery is the preferred approach for most early-stage endometrial cancers and many other gynecological procedures, offering faster recovery with comparable cancer outcomes in large studies.
Potential benefits:
Important: For early cervical cancer requiring radical hysterectomy, a major international trial (LACC) found higher recurrence rates with minimally invasive surgery, so open surgery is generally recommended for most patients. Advanced ovarian cancer also usually requires open surgery. Your surgeon will recommend the safest approach for your cancer.
Debulking (cytoreductive) surgery removes as much ovarian cancer as possible, ideally leaving no visible tumor, which is one of the strongest predictors of long-term survival.
Chemotherapy is a standard part of treatment for most ovarian cancers and for many advanced cervical and endometrial cancers, commonly given as six cycles over about four to five months.
Table 16. Common systemic treatment schedules at a glance
| Treatment | Cancer Type | How Often | Typical Course | Setting / Time per Visit |
|---|---|---|---|---|
| Carboplatin + paclitaxel | Ovarian, endometrial | Every 3 weeks | 6 cycles (about 18 weeks) | Day care; about 4–6 hours |
| Weekly cisplatin with radiation | Cervical, vulvar, vaginal | Weekly | 5–6 doses over 5–6 weeks | Day care; about 3–4 hours with hydration |
| PARP inhibitor (olaparib, niraparib) | Ovarian (maintenance) | Daily tablets | Up to 2–3 years, depending on drug | At home; monthly review and blood tests |
| Bevacizumab | Ovarian, cervical | Every 3 weeks | Often about 12–15 months in total | Day care; about 30–90 minutes |
| Immunotherapy (pembrolizumab, dostarlimab) | Endometrial, cervical | Every 3–6 weeks | Up to about 2–3 years | Day care; about 30–60 minutes |
Schedules are typical examples. Your regimen may differ based on your cancer, blood counts and tolerance.
Radiation therapy uses precisely targeted high-energy beams to destroy cancer cells and is a curative treatment for many cervical, vaginal and vulvar cancers.
Table 17. Radiation treatment types and schedules
| Type | How It Works | Used For | Typical Schedule |
|---|---|---|---|
| External beam radiation (IMRT / VMAT / IGRT) | Shaped beams from a machine that spare the bladder and bowel | Cervical, vulvar, vaginal and high-risk endometrial cancer | 25–28 daily sessions, 5 days a week, over 5–6 weeks; about 15–20 minutes each |
| Brachytherapy for cervical cancer | Radiation source placed temporarily inside the uterus and vagina | Cervical cancer (a key part of curative treatment) | Usually 3–5 sessions, after or during external beam |
| Vaginal cuff brachytherapy | Cylinder placed in the vagina to treat its upper portion | After endometrial cancer surgery | 2–6 outpatient sessions over 1–3 weeks; about 30 minutes each |
| Stereotactic radiation (SBRT) | Very precise, high-dose treatment | Limited recurrences or metastases | 1–5 sessions |
Timing matters: For locally advanced cervical cancer, completing chemoradiation and brachytherapy within about eight weeks is associated with the best chance of cure.
Targeted therapies attack specific molecular weaknesses in cancer cells, and PARP inhibitors are among the most significant recent advances in ovarian cancer treatment.
Availability and regulatory approvals vary by country. Your oncologist will recommend targeted therapy based on your biomarker results.
For many advanced endometrial and cervical cancers, immunotherapy is now a standard treatment option and can produce long-lasting responses in some women.
HIPEC (hyperthermic intraperitoneal chemotherapy) is heated chemotherapy circulated through the abdomen during surgery, and it may improve survival for carefully selected women with advanced ovarian cancer.
A tumor board is a meeting where specialists from each relevant field review your case together to agree on a recommended treatment plan.
Clinical trials offer access to promising new treatments and may be a suitable option for women at many stages of gynecological cancer.
Side effects depend on the treatment you receive; many are temporary, and most can be reduced with modern supportive care.
Table 18. Common side effects and how they are managed
| Treatment | Common Side Effects | How They Are Managed |
|---|---|---|
| Surgery | Pain, tiredness, wound healing issues, blood clots, bladder or bowel changes, lymphedema, surgical menopause | Enhanced recovery (ERAS) protocols, early mobilisation, blood thinners, physiotherapy |
| Chemotherapy | Fatigue, nausea, hair loss, low blood counts and infection risk, numbness or tingling (neuropathy), mouth sores | Anti-nausea medicines, growth factor injections, dose adjustments, regular blood tests |
| Pelvic radiation | Diarrhea, bladder irritation, skin soreness, fatigue, vaginal dryness and narrowing | Dietary changes, medications, vaginal dilators, skin care |
| PARP inhibitors | Anemia, low platelets, nausea, fatigue | Regular blood counts, dose reduction or short breaks |
| Bevacizumab | High blood pressure, protein in urine, delayed wound healing | Blood pressure and urine monitoring |
| Immunotherapy | Thyroid problems, skin rash, diarrhea or colitis, inflammation of lungs or liver | Early reporting, steroids or hormone replacement as needed |
Most women who receive carboplatin and paclitaxel, a standard chemotherapy for ovarian and endometrial cancer, lose their hair, and in most women it grows back after treatment.
Table 19. Typical hair loss and regrowth timeline
| Stage | Typical Timing* |
|---|---|
| Hair thinning begins | 2–3 weeks after the first cycle |
| Most hair lost | By the second or third cycle |
| Regrowth begins | Usually within 1–3 months after the last cycle |
| Reasonable coverage | Around 3–6 months after finishing |
| Texture or colour changes | May occur temporarily with new growth |
*Timelines vary between individuals.
Fatigue, nausea and neuropathy are common treatment side effects, and each can often be reduced with a combination of medication and self-care.
Lymphedema is swelling of the legs or genital area caused by damage to lymph nodes from surgery or radiation, and its risk can be reduced with sentinel lymph node techniques and early care.
Contact your oncology team immediately, day or night, if you develop a temperature of 38°C (100.4°F) or above during chemotherapy, as this may signal a serious infection.
Table 20. When to contact your care team
| Symptom | Threshold | Action |
|---|---|---|
| Fever or chills | 38.0°C (100.4°F) or above, or shivering | Call immediately / go to emergency |
| Breathlessness or chest pain | Any new or sudden onset | Go to emergency care |
| Vaginal bleeding | Soaking a pad every hour | Go to emergency care |
| Diarrhea | More than 4–6 episodes a day above your normal, or lasting over 24 hours | Call the same day |
| Vomiting | Unable to keep fluids down for 12–24 hours | Call the same day |
| Leg pain or swelling | One leg red, painful or swollen | Call the same day (possible blood clot) |
| Confusion or severe headache | Any new episode | Go to emergency care |
Follow any specific thresholds your own team gives you. +91 88840 09955
For selected women with early-stage gynecological cancer, fertility-sparing treatment is possible, so discuss fertility with your oncologist before treatment begins.
Table 21. Fertility-sparing options
| Cancer Type | Fertility-Sparing Option | Who May Be Eligible |
|---|---|---|
| Cervical cancer | Cone biopsy or radical trachelectomy (removing the cervix while keeping the uterus) | Small, early-stage tumors (generally stage IA to IB1, 2 cm or less) |
| Endometrial cancer | Hormonal (progestin) therapy, often with a hormone-releasing IUD, and close monitoring | Low-grade (grade 1) endometrioid cancer confined to the uterine lining |
| Ovarian cancer | Removal of only the affected ovary and tube, preserving the uterus and other ovary | Selected early-stage epithelial tumors, borderline tumors and germ cell tumors |
| Any cancer needing pelvic radiation or chemotherapy | Egg, embryo or ovarian tissue freezing; moving the ovaries out of the radiation field (ovarian transposition) | Women wishing to preserve fertility who can safely delay treatment briefly |
Removing both ovaries or giving pelvic radiation causes menopause in premenopausal women, and some chemotherapy can also stop ovarian function.
Possible symptoms:
Treatment options:
Many women resume a satisfying sex life after gynecological cancer treatment, although some adjustments and support may be needed.
Some gynecological cancers are hereditary: up to about one in five ovarian cancers and around 3–5% of endometrial cancers are linked to an inherited gene mutation.
Table 22. Inherited conditions and gynecological cancer risk
| Inherited Condition | Associated Cancers | Approximate Lifetime Risk |
|---|---|---|
| BRCA1 mutation | Ovarian, fallopian tube, breast | Ovarian cancer: roughly 39–44% |
| BRCA2 mutation | Ovarian, breast, pancreatic, prostate | Ovarian cancer: roughly 11–17% |
| Lynch syndrome (MLH1, MSH2, MSH6, PMS2) | Endometrial, ovarian, colorectal | Endometrial cancer: up to about 40–60% depending on the gene |
| Other genes (RAD51C, RAD51D, BRIP1, PALB2) | Ovarian, breast | Moderately increased ovarian cancer risk |
A BRCA mutation is associated with a higher likelihood of response to platinum chemotherapy and PARP inhibitor maintenance, which can keep ovarian cancer in remission for longer.
Your genetic results may also influence:
If you carry an inherited mutation, each of your parents, siblings and children has a 50% chance of carrying it, and knowing this can help them take preventive steps.
Cervical cancer is one of the most preventable cancers, and the risk of several other gynecological cancers can be substantially reduced.
Most women aged 25 or 30 to 65 are advised to have cervical screening every five years with an HPV test, or every three years with a Pap smear alone.
Table 23. Cervical screening intervals by age
| Age Group | Recommended Screening (typical international guidance) |
|---|---|
| Under 21–25 | Routine screening is not recommended |
| 21/25 to 29 | Pap smear every 3 years, or primary HPV test every 5 years from age 25 where available |
| 30 to 65 | Primary HPV test every 5 years (preferred), co-testing (HPV + Pap) every 5 years, or Pap alone every 3 years |
| Over 65 | Screening may stop after consistently normal results in the previous 10 years |
| After hysterectomy for benign reasons | Usually not needed if the cervix was removed and there was no history of precancer |
Recommendations differ between countries. The World Health Organization recommends HPV-based screening from age 30. Follow your doctor's advice and local guidelines.
There is currently no proven screening test for ovarian cancer in women at average risk, which is why knowing the symptoms is so important.
The HPV vaccine is highly effective and, when given before exposure to HPV, can prevent the large majority of cervical cancers.
Table 24. HPV vaccination by age
| Age | Recommendation |
|---|---|
| 9–14 years (girls and boys) | Ideal age; before sexual activity begins |
| 15–26 years | Catch-up vaccination recommended in many countries |
| 27–45 years | May benefit some adults; discuss with your doctor |
Recurrence risk depends on the type and stage of your cancer: it is low for many early-stage endometrial and cervical cancers and higher for advanced ovarian cancer.
Follow-up care involves regular check-ups with your oncology team, most frequently in the first two to three years after treatment when recurrence risk is highest.
Table 25. Typical follow-up schedule after treatment
| Time Since Treatment | Typical Visit Frequency | What Is Checked |
|---|---|---|
| Years 1–2 | Every 3–4 months | Symptoms, physical and pelvic examination, CA-125 or other markers where relevant, side effect management |
| Years 3–5 | Every 6 months | Examination, tests as indicated, bone and heart health, sexual and emotional wellbeing |
| After 5 years | Once a year | Long-term survivorship care, screening for other cancers, healthy lifestyle support |
Recurrent gynecological cancer can often still be treated, and many women live for years with good quality of life after a recurrence.
A balanced, mainly plant-based diet and regular physical activity support energy, strength and quality of life after gynecological cancer, and may lower recurrence risk for some cancers.
Feeling shocked, frightened, angry or low after a cancer diagnosis is common and understandable, and professional emotional support is an important part of cancer care.
Many women continue working during treatment, often with adjusted hours or duties, although most need some time off after surgery.
Table 26. Planning work around treatment
| Treatment Phase | Typical Impact on Work* |
|---|---|
| Keyhole (robotic / laparoscopic) surgery | 2–4 weeks off |
| Open surgery | 6–8 weeks off; longer after debulking surgery |
| Chemotherapy every 3 weeks | Often most tired for 3–7 days after each cycle; many work part-time |
| Daily radiation (5–6 weeks) | Daily appointment of about 30–60 minutes including travel; fatigue builds toward the end |
| Maintenance tablets or immunotherapy | Most women can work normally |
*Individual experiences vary.
The cost of gynecological cancer treatment varies widely with the type of treatment, number of cycles or sessions and length of hospital stay, and many health insurance plans cover a large part of it.
Table 27. Cost estimate overview (to be completed by hospital)
| Treatment | Estimated Cost Range | Typically Covered by Insurance? |
|---|---|---|
| Robotic / laparoscopic hysterectomy | [₹ / $ range] | [Yes / Partial] |
| Cytoreductive surgery | [range] | [ ] |
| Chemotherapy (per cycle) | [range] | [ ] |
| Radiation therapy (full course) | [range] | [ ] |
| Targeted therapy / immunotherapy (per month) | [range] | [ ] |
Preparing a list of questions before your first appointment helps you understand your diagnosis and take an active part in treatment decisions.
Table 28. What to bring to your first appointment
| Item | Why It Helps |
|---|---|
| Referral letter and prior consultation notes | Gives the team your full history |
| Pathology reports and biopsy slides / blocks | Allows review of the diagnosis |
| Scan CDs and reports (ultrasound, CT, MRI, PET-CT) | Avoids unnecessary repeat scans |
| Blood test results, including tumor markers | Provides a baseline |
| List of current medicines and allergies | Ensures treatment is safe |
| Insurance card and ID | Speeds up registration and pre-authorisation |
| A family member or friend | Helps with listening, notes and support |
At Aster Whitefield Hospital, women with gynecological cancer receive care from a dedicated multidisciplinary team at every step:
Book a consultation with a gynecologic oncologist. Call +91 88840 09955 or /contact/ to schedule an appointment or request a second opinion.
Medical disclaimer: This information is for general education and does not replace professional medical advice. Survival statistics, timelines and treatment options are general and may not apply to your situation. Always consult your treating oncologist.
Medically reviewed by Dr Ashwin K.R. · Last reviewed: 10 October 2026
Medical disclaimer: This information is for general education and does not replace personalised medical advice. Please consult a qualified doctor about your specific diagnosis and treatment.